Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 22, 2017

Study Completion Date

September 22, 2017

Conditions
Acute Myeloid LeukemiaNeutropeniaInfection
Interventions
BIOLOGICAL

CLT-008

Single intravenous infusion

BIOLOGICAL

G-CSF

Daily subcutaneous injections

Trial Locations (22)

10065

Weill Cornell Medical College - New York Presbyterian Hospital, New York

10595

Westchester Medical Center, Valhalla

15224

West Penn Hospital, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

30342

Northside Hospital, Atlanta

32224

Mayo Clinic Florida, Jacksonville

32608

UF Health Shands Cancer Hospital, Gainesville

46237

Indiana Blood and Marrow Transplantation Clinic, Indianapolis

55455

University of Minnesota Physicians BMT Clinic, Minneapolis

60153

Loyola University Medical Center, Maywood

60611

Northwestern Medical Faculty Foundation, Chicago

60612

University of Illinois Cancer Center, Chicago

60637

The University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

64128

Kansas City Veterans Affairs Medical Center, Kansas City

66215

Memorial Sloan Kettering Cancer Center, New York

77030

The University of Texas MD Anderson Cancer Center, Houston

90095

Ronald Reagan UCLA Medical Center, Los Angeles

92093

University of California San Diego Moores Cancer Center, La Jolla

94143

University of California, San Francisco Medical Center, San Francisco

98104

Swedish Cancer Institute, Seattle

01655

University of Massachusetts Worcester, Worcester

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Cellerant Therapeutics

INDUSTRY